

Inheritance of IVSI-I Mutation Assures 158 (C-T) XmnI Polymorphism in Thalassemia Intermedia

Shakila ASHRAF¹, Moinuddin MOINUDDIN²

¹ Sultan Qaboos University, Department of Haematology, Muscat, OMAN

² Baqai Medical University, Department of Hematology, Karachi, PAKISTAN

ABSTRACT

Thalassemia intermedia lies between asymptomatic β -thalassemia carrier state to severe thalassemia Major. XmnI polymorphism is one of the modifying factors of intermedia phenotype. This study intendeds to determine the frequency of Xmn-I polymorphism and its association with different beta chain mutations that would contribute towards the phenotype. 100 whole blood samples of thalassemia intermedia patients were tested for the common beta chain mutations found in Pakistan and then tested for Xmn-I polymorphism. The most common mutation identified in these patients was IVSI-5. Xmn-I polymorphism was found in 79% of the patients, 36% being homozygous and 43% being heterozygous. Xmn-I polymorphism was found in 84.7% of the samples with IVSI-5 mutation, 52.1% of Fr 8-9, 45% of Cap+1, 85.7% of Cd30, 91.66% of HbE, and 33.3% of the samples with del619 mutation. Whereas $\delta\beta$, HbS, IVSI-I showed 100% positivity for Xmn-I polymorphism. The age of start of transfusion was 3 -9 years and had high hemoglobin F levels. All the samples with IVSI-I mutation were homozygous (+/+) for Xmn-I polymorphism. Thus a firm linkage between the XmnI polymorphism and IVSI-I mutation is suggested and that IVSI-I mutation always accompany homozygosity of Xmn-I polymorphism and the coinheritance of the two mutations will lead to a milder phenotype.

Keywords: Thalassemia intermedia, Xmn-I polymorphism, IVSI-I mutation, HbS, $\delta\beta$ thalassemia

ÖZET

Talasemi İntermediada IVSI-I Mutasyon Kalıtımı, 158 (C-T) Xmn-I Polimorfizmini Sağlar

Talasemi intermedia, asemptomatik β -talasemi taşıyıcılık durumu ile ciddi talasemi major arasındadır. İntermediate fenotipte hastalığı modifiye eden faktörlerden biri Xmn-I polimorfizmidir. Bu çalışmada talasemi intermedia hasta grubunda, Xmn-I polimorfizmi sıklığını ve farklı beta zincir mutasyonları ile ilişkisini ve fenotipe olan katkısını incelemeyi amaçladık. Pakistan'da Talasemi intermedia hastası olan 100 kişiden kan örnekleri alındı ve bu örneklerde beta zincir mutasyonu ve Xmn-I polimorfizmi çalışıldı. Bu hastalarda tespit edilen en sık mutasyon IVSI-5 idi. Xmn-I polimorfizmi %79 hastada bulundu; bunların %36'sı homozigot iken %43'ü ise heterozigot idi. IVSI-5 mutasyonlarında Xmn-I polimorfizmi %84.7 oranında saptanırken, Fr 8-9'da %52.1, Cap+1'de %45 Cd30'da %85.7, HbE, %91.66'da del619 mutasyonu olanlarda ise % 33.3 oranında saptandı. Ancak $\delta\beta$, HbS, IVSI-I'lı grupta Xmn-I polimorfizmi %100 pozitif idi. Bu hastaların transfüzyona başlama yaşı 3-9 yaş arasında ve yüksek hemoglobin F seviyelerine sahip idiler. IVSI-I mutasyonu olan hastaların hepsinde homozigot (+/+) Xmn-I polimorfizmi var idi. IVSI-I mutasyonu ve Xmn-I polimorfizmi arasındaki önemli ilişkiye dayanarak şunu önerebiliriz; IVSI-I mutasyonu her zaman Xmn-I polimorfizmine eşlik etmektedir. Bu eş zamanlı mutasyonun varlığı daha hafif seyirli fenotipe neden olmaktadır.

Anahtar Kelimeler: Talasemi intermedia, Xmn-I polimorfizmi, IVSI-I mutasyonu, HbS, $\delta\beta$ talasemi

INTRODUCTION

Thalassemia intermedia describes the condition with clinical manifestations that is between asymptomatic β -thalassemia carrier to severe thalassemia Major.¹ This significant clinical heterogeneity fall-out from different genetic determinants influencing the clinical outcome of the disease.²⁻⁶ The underlying genetic diversity can best be enlightened by primary, secondary, and tertiary genetic modifiers.⁷ High percentage of XmnI polymorphism has been found in thalassemia intermedia patients.⁸ Xmn-I G γ polymorphism in association with homozygous β^0 -thalassemia is one of the renowned phenotype modifying factors.^{3,9-11} Xmn-I polymorphism is heterogeneously distributed in different parts of the world.^{12,13} However the molecular mechanisms describing the effects of beta thalassemia mutations on the distribution of XmnI polymorphism are not well outline. This study intendeds to determine the frequency of Xmn-I polymorphism and its association with different beta chain mutations that would determine the contribution towards the milder phenotype.

PATIENTS AND METHODS

Whole blood samples of 100 thalassemia Intermedia patients were collected. The study was approved by the Institutional Ethics Committee. An informed consent was taken from the patients before sample collection. Information of each patient regarding their age, sex, ethnic group, commencement of transfusion and clinical appearance was noted at the time of sample collection. The criteria for the inclusion of the patients for this study was, that the patient be known thalassemic, age at start of transfusion was more than three years and the interval between the transfusion was at least one month.

Complete blood counts of the samples were carried out. The samples were then tested for the common beta chain mutations found in Pakistan by multiplex amplified refractory mutation system PCR. Samples were then tested for Xmn-I polymorphism. In order to demonstrate this polymorphism, a 641bp fragment of DNA flanking the polymorphism was amplified using the following primers.

Table 1. Xmn-I G γ Genotype in TI Patients

Xmn-I genotype	Frequency	Cumulative percentage
-/+	43	43
+/+	36	79
-/-	21	0
Total	100	

5' – GAA CTT AAG AGA TAA TGG CCT AA
5' – ATG ACC CAT GGC GTC TGG ACT AG
The reaction mixture was prepared by adding 20 μ l of buffer, 1 μ l of primer, 2 μ l of DNA and 0.1 μ l of Taq. The PCR conditions for the RFLP protocol was 94°C for 1 minute of denaturation , annealing at 60°C for 1 minute, extension at 72°C for 1 minute and 3 minutes of final extension at 72°C. Numbers of cycles carried out were 30. Amplified fragment was digested with 10 units of enzyme Pdm-I (Fermentus) at 37°C overnight and the results were recorded after electrophoresis on 6% Acrylamide gel. The calculations were carried out using SPSS version 17.

RESULTS

Xmn-I polymorphism was located in 79% of the samples, 36% of the samples were homozygous (+/+), 43% were heterozygous (-/+) and 21% were negative for Xmn-I polymorphism (Table 1). IVSI-5 mutation declared 92% of the alleles, Fr 8-9 was 23% and Cap+1 20% of the total alleles. IVSI-I was found in 15% of the patients and $\delta\beta$ in 10% of the patients, both the mutations showed 100% positivity for homozygous Xmn-I polymorphism (+/+). HbS was found in 6% of the samples, out of which 4 were heterozygous (-/+) and 2 were homozygous (+/+) for Xmn-I polymorphism. Percentages of the rest are given in Table 2. 52% of the samples were homozygous and 46% of the samples were heterozygous for the beta chain mutations. IVSI-5 / IVSI-5 genotype was found in 29% of the patients, out of which 13% were homozygous, 12% were heterozygous, and 4% were negative

Table 2. Xmn-I polymorphism in different mutations

Mutation	Number	Xmn-I polymorphism			Xmn-I positivity
		-/-	-/+	+ / +	
IVSI-5	92	14	43	35	78 (84.7)
Fr 8-9	23	11	12	0	12 (52.1)
Cap+1	20	11	7	2	9 (45)
IVSI-I	15	0	0	15	15 (100)
Cd30	14	2	6	6	12 (85.7)
HbE	12	1	6	5	11 (91.6)
δβ	10	0	0	10	10 (100)
HbS	6	0	4	2	6 (100)
Del 619	3	2	1	0	1(33.3)
Cd15	2	0	2	0	2 (100)
Fr 41- 42	1	0	1	0	1 (100)
Fr16	1	1	0	0	0
Unknown	1	0	1	0	1 (100)
Total	200				

for Xmn-I polymorphism. The genotype IVSI-5 / Cap+1 was found in 11 percent of the patients under study, out of which 2% were homozygous, 5% were heterozygous and 4% were negative for Xmn-I polymorphism (Table 3).

Xmn-I polymorphism was found in 79% of the patients (Table 2). 52% of the samples were homozygous and 46% of the samples were compound heterozygous for beta chain mutation.

DISCUSSION

The most common mutation identified in this group of thalassemia intermedia patients was IVSI-5. A strong link was observed between IVSI-I and Xmn-I polymorphism. All the samples with IVSI-I mutation were homozygous for Xmn-I polymorphism. The age at start of transfusion was 3-9 years and had high hemoglobin F levels. Five of the samples being homozygous for the IVSI-I mutation

(IVSI-I/IVSI-I) were homozygous for Xmn-I polymorphism and five of the samples were compound heterozygous for IVSI-I / IVSI-5 mutations, out of which 3 had -/+ and 2 had +/+ Xmn-I polymorphism genotype (Table 3) but none of them was Xmn-I polymorphism negative. Such a strong association of the Xmn-I and IVSI-I suggests a possible linkage between the two molecular defects. Thus suggesting the assurance of coexistence of IVSI-I mutation with Xmn-I polymorphism and would pedestal the appearance of thalassemia intermedia phenotype. But the molecular defect describing their coinheritance is yet to be investigated.

Xmn-I gene polymorphism is known to be one of the main phenotype modifying factors of β-thalassemia.¹⁴ C-T polymorphism at 158 base pair upstream Gc gene (XmnI polymorphism) may affect the haemoglobin F production leading to remodeling of thalassemia phenotype.^{12,15} It has been documented that the presence of Xmn-1(G) gamma

Table 3. Frequency of Xmn-I polymorphism in heterozygous and homozygous beta thalassemia intermedia.

Mutations identified	Xmn-I			Total	Mutations identified	Xmn-I			Total
	+/+	-/+	-/-			+/+	-/+	-/-	
IVSI-5 / IVSI-5	13	12	4	29	IVSI-5 / Cap+1	2	5	4	11
Fr 8-9 / Fr 8-9		4	3	7	IVSI-5 / HbE	3	5	1	9
IVSI-I / IVSI-I	5			5	IVSI-5 / IVSI-I	2	3		5
δβ	5			5	Fr 8-9 / Cap+1		1	3	4
Cd30 / Cd30	3	1		4	IVSI-5 / HbS	2	1		3
Cd15 / Cd15		1		1	Del 619 / Cap+1			2	2
HbE / HbE	1			1	Fr 8-9 / Cd30		1	1	2
Total				52	Cap+1 / HbS		1		1
Fr 8-9/ Unknown		1		1	Cd30 / Cap+1			1	1
					Cd30 / HbE		1		1
					Cd30 / HbS		1		1
					Fr 8-9 / HbE		1		1
					Fr16 / Cap+1			1	1
					IVSI-5 / Cd30		1		1
					IVSI-5 / Del 619		1		1
					IVSI-5 / Fr 41-42		1		1
					IVSI-5 / Fr 8-9			1	1
					Total				46

polymorphism with IVS1-1(G- T) results in late clinical presentation and is associated with variable progress with hydroxyurea therapy.^{16,17} IVSI-I is an RNA splicing mutation.¹⁸ Mutations that affect either of the invariant dinucleotides in the splice junction completely abolish normal splicing and produce the phenotype of β° thalassemia. Genes bearing these mutations appear to transcribe normally and, although some alternative splicing occurs using “cryptic” donor or acceptor sites, the misspliced mRNA do not translate into functional β globin. Thus mutations at splice junctions of exon 1/IVS1, IVS1/exon 2 and exon 2/IVS2 all abolish normal splicing causing a β° thalassemia phenotype.^{19,20} These patients in spite of having the mutations that lead to a β° thalassemia presented

with milder phenotype. Thus the milder phenotype might be a result of the co inheritance of the Xmn-I polymorphism.

In this study all the 6 patients with HbS were positive for Xmn-I polymorphism either in homozygous or heterozygous form. It has been reported that Gγ-polymorphism increases the production of Hb-F, reducing the severity of the disease.^{15,21-23} Thus envisage that presentation of HbS with the support of Xmn-I polymorphism presents in thalassemia intermedia phenotype.

Similar association was demonstrated between Gγ (Aγ δβ)° and XmnI polymorphism in this study where 5 of the samples were homozygous for Gγ (Aγ δβ)° mutations and all were also homozygous

for XmnI polymorphism. This is in accordance of a study by Ahmed S 2005. Thus XmnI polymorphism is linked to completely deleted beta gene as in the case of $\delta\beta$ thalassaemia where it can be assumed that the loss of regulatory regions for the c-genes, the rearrangement of the b-gene complex that brings enhancer sequences close to the Gc-globin gene promoter, and the loss of competition for a common locus control region (LCR) between the c-, d-, and the b-gene promoters may be involved.¹⁵

The aptitude to predict phenotype from genotype has important implication for the screening of beta-thalassemia carriers, for genetic counseling and prenatal diagnosis and for setting up an appropriate treatment regimen. Therefore it is important to have genotype analysis to establish an early diagnosis of mild beta-thalassemia. Nevertheless because of the genetic and environmental modifying factors it is still a challenge to predict thalassemia intermedia phenotype.²¹

Conclusion

As a conclusion our results strongly suggest a firm linkage between the XmnI Gg polymorphism and IVSI-I mutation. Presence of IVSI-I mutation declares homozygosity of Xmn-I polymorphism and the coinheritance of these mutations leads to the intermedia phenotype.

Homozygous $G\gamma$ ($A\gamma$ $\delta\beta$)^o) and HbS also shows strong association to Xmn-I polymorphism. Thus it is reasonable to speculate that we have contained the principal genetic defect in this illustration and that it leads to the observed phenotype.

Acknowledgments

I would like to extend my deepest gratitude to Gen. Suhaib Ahmed of Armed forces institute of pathology, Rawalpindi for his marvelous supervision in the study. Thanks are also due for the technical staff of the institute for their tremendous support. The research work was partially funded by baqai institute of hematology, PNS shifa Karachi, Armed forces institute of hematology Rawalpindi plus including some self funds.

Funding source

The project was self supported but partially funded by Baqai Medical University, Armed forces institute of hematology, Rawalpindi and PNS shifa Karachi.

REFERENCES

1. Thi Khanh TN, Philippe J, Claire BI, et al. The XmnI $G\gamma$ polymorphism influences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 β -thalassaemia intermedia patients. *Blood Cells Mol Dis* 45: 124-127, 2010.
2. Anthony H, Paul T, Amr R, et al. β -Thalassaemia Intermedia: A Bird's-Eye View. *Turk J Hematol* 31: 5-16, 2014.
3. Anzel B, Erol OA. Frequency of $G\gamma$ -globin promoter -158 (C>T) Xmn I polymorphism in Denizli, Turkey. *Int J Physic Sci* 7: 1927-1931, 2012.
4. Wanqun C, Xinhua Z, Xuan S, et al. The molecular basis of beta-thalassaemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity. *BMC Med Genet* 11: 31, 2010.
5. Rachid H, Hani M, Ali T. Paraspinal extramedullary hematopoiesis in patients with thalassaemia intermedia. *Eur Spine J* 19: 871-878, 2010.
6. Ali T, Hussain NI, Maria D, Cappellini A. Thalassaemia intermedia: Revisited. *Blood Cells Mol Dis* 37: 12-20, 2006.
7. Renzo G. Recent advances in the molecular understanding of non-transfusion-dependent Thalassaemia. *Blood Rev* 26: 7-11, 2012.
8. Tamoor BH, Suhaib A, Jaleel A, Syed Kazim AK. XmnI Polymorphism and disease severity in patients with beta thalassaemia from northern Pakistan. *J Ayub Med Coll Abbottabad* 27: 13-16, 2015.
9. Maryam Neishabury N, Azita A, Hossein N. Frequency of Positive XmnI $G\gamma$ polymorphism and coinheritance of common alpha thalassaemia mutations do not show statistically significant difference between thalassaemia major and intermedia cases with homozygous IVSII-1 mutation. *Blood Cells Mol Dis* 44: 95-99, 2010.
10. Amel Haj K, Madeleine M, Sandrine L, et al. Xmn I polymorphism associated with concomitant activation of $G\gamma$ and $A\gamma$ globin gene transcription on a β^o -thalassaemia chromosome. *Blood Cells Mol Dis* 46: 133-138, 2011.
11. Shawky RM, Kamal TM. Thalassaemia intermedia: An overview. *The Egyptian Journal of Medical Human Genetics* 13: 245-255, 2012.
12. Nadir A, Muhammad A, Saleem Ahmed K, et al. Frequency of Gc-globin promoter -158 (C>T) XmnI polymorphism in patients with homozygous/compound heterozygous beta thalassaemia. *Hematol Oncol Stem Cell Ther* 8: 10-15, 2015.

13. Lalana N, Supan F, Goonnapa F, et al. Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E- β -thalassemia in Northeast Thailand. *Blood Cells Mol Dis* 42: 32-35, 2009.
14. Said F, Abdel-Salam A. Xmn1 polymorphism: Relation to β -thalassemia phenotype and genotype in Egyptian Children. *Egypt J Med Hum Genet* 12: 2014. <http://dx.doi.org/10.1016/j.ejmhg.2014.12.005>
15. Ahmed S, Anwar M. Xmn1 Ggamma-polymorphism in six unrelated Pakistani families with Inv/ Del Ggamma (Agam-madeltabeta) degrees delta beta thalassemia. *Am J Hematol* 80: 303-305, 2005.
16. Sharma N, Das R, Kaur J, et al. Evaluation of the genetic basis of phenotypic heterogeneity in north Indian patients with thalassemia major. *Eur J Haematol* 84: 531-517, 2010.
17. Fadwa S, Amina AS. Xmn1 polymorphism: Relation to β -thalassemia phenotype and genotype in Egyptian Children. *Egypt J Med Hum Genet* 16: 123-127, 2015.
18. Hamid G, Mohammad P, Bahaoddin S, Behnaz A. Wide Spectrum of Mutations in the Beta-Globin Gene Causing Beta-Thalassemia Major in Southwest Iran. *Iranian J Pediatr Soc* 2: 4-8, 2010.
19. Ho PJ, Thein SL. Gene regulation and deregulation: a β globin perspective. *Blood Rev* 14: 78-93, 2000.
20. Stuart HO, Sabra CG, Rachel LH. Mutation in an intervening sequence splice junction in man α -thalassemia/gene cloning/ DNA sequence analysis/RNA processing/stable RNAs. *Proc Natl Acad Sci USA* 78: 5041-5045, 1981.
21. Ali T, Hussain I, Maria DC. Thalassemia intermedia: Revisited. *Blood Cells Mol Dis* 37: 12-20, 2006.
22. Dabke P, Colah RB, Ghosh K, Nadkarni A. Effect of a group of genetic markers around the 5 regulatory regions of the β globin gene cluster linked to high HbF on the clinical severity of β thalassemia. *Blood Cells Mol Dis* 1: 156-160, 2013.
23. Dadheech S, Suman J, Madhulatha D, et al. Association of Xmn1 2158 cG variant with severity and HbF levels in β -thalassemia major and sickle cell anaemia. *Mol Biol Rep* 41: 3331-3337, 2014.

Correspondence

Dr. Shakila ASHRAF
P. O Box 38. Al-khodh
MUSCAT / OMAN

Tel: 0096897158837
Fax: 0096824144887
e-mail: shakila_ashraf@hotmail.com
shakila@squ.edu.om